首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 製藥 > 藥物開發 > HIV治療藥發展:新技術趨勢
產業/市場分類
製藥 (4452)
肥胖症治療 (48)
非專利藥 (117)
疫苗 (167)
神經疾病 (175)
骨頭疾病治療 (40)
動物用醫藥 (18)
處方藥 (89)
規章 (107)
感染疾病 (315)
精神病 (80)
製藥企業 (500)
糖尿病 (157)
癌症 (837)
藥物開發 (1246)
DDS (173)
OTC 非處方藥 (147)
市場調查報告書

HIV治療藥發展:新技術趨勢

HIV Drug Development--Emerging Technologies

出版商 Technical Insights, Inc.
出版日期 2006年06月 商品編碼 45029
內容資訊 英文  
價格
US $ 6000 Web Access (Regional License)
US $ 6500 Hard Copy & Web Access (Regional License)


HIV治療藥發展:新技術趨勢 是由出版商Technical Insights, Inc.在2006年06月所出版的。 這份英文市場調查報告書價格從美金6000起跳。

簡介

現在具體可知的是抗逆轉錄病毒藥對將近78%的患者而言沒有效果。1999年未接受治療患者當中有8%有抗藥反應,而現在該比率已上昇到20%。為了研發出更多可治療患者的藥劑,抗藥性測試扮演重要的角色。

專門於多樣先進產業相關策略性調查的美國市調公司 Technical Insights, Inc. (總公司:德州),針對HIV治療藥發展趨勢進行調查分析,經系統整理調查結果後出版報告書 "HIV Drug Development--Emerging Technologies" 。

本報告書內容包括:發展HIV治療藥的新技術及既有技術的新應用領域、最新研發趨勢、產品發展及法規限制趨勢等。內容綱要摘記如下:

第1章 實施概要

  • 介紹
    • HIV介紹
    • 患者人數
  • 調查範圍及方法
    • 範圍
    • 方法

第2章 技術及應用趨勢

  • 主要技術
    • 藥品
    • 疫苗
    • 殺菌劑
    • Red Ribbon Project
  • 趨勢及重要的醫療實驗
    • 發展中
    • 全球情勢
    • 重要的醫療實驗趨勢

第3章 技術導入要因分析

  • 促進因素及課題
  • 法規限制的障礙及財政
  • 亞太地區的發展

第4章 最新技術趨勢:藥品

  • 最新技術:企業
    • 治療HIV用之利用病毒侵入抑制劑的單細胞繁殖抗體:美國
    • 保護健康細胞不受HIV傳染之新的侵入抑制劑:加拿大
    • 治療HIV用的創新侵入抑制劑:美國
    • 預防HIV傳染用之核苷逆轉錄酵素抑制藥治療:美國
    • 避免細胞複製時必要氧化作用的藥劑:美國
    • 預防HIV傳染的侵入抑制劑:美國
    • 避免細胞受到新的傳染用的逆轉錄酵素抑制劑:美國
    • 以HIV傳染為目標之促進抗病毒作用的端粒脢(Telomerase):中國
  • 最新技術:研究機構
    • 有助於藥品研發的宿主和病毒間相互作用
    • 科學家們發現分子與宿主基因構造和HIV的結合有關

第5章 最新技術:疫苗、殺菌劑

  • 企業的最新技術:疫苗
    • AdVac疫苗:荷蘭
    • DNA疫苗:美國
    • 單細胞繁殖:美國
    • 以植物為基礎的HIV疫苗:美國
    • Therapore Technology的HIV疫苗:美國
    • 針對AIDS疫苗的Dendritic Cell Technology:英國
  • 企業的最新技術:殺菌劑
    • 預防HIV傳染用的凝膠狀殺菌劑:加拿大
    • 預防HIV傳染用的殺菌凝膠:澳洲
    • 預防HIV傳染用的殺菌凝膠:美國
    • 預防HIV傳染用的寡核酸殺菌劑:美國
    • 做為局部殺菌劑的間二氮雜苯(Pyrimidine)類產品
  • 研究機構
    • 利用基因重組香烟做成的HIV疫苗:美國
    • 妨礙HIV複製的逆轉錄病毒策略:印度
    • 疫苗研發用的脂質體佐劑:印度
    • 以HIV為治療目標的腺載體疫苗:美國
    • 針對HIV的抗病毒策略的新目標:印度
    • 針對HIV的植物疫苗:俄羅斯

第6章 專利、聯絡對象、名詞解釋

  • 專利
  • 聯絡對象及名詞解釋

第7章 Frost & Sullivan 獎

第8章 決策支援資料庫

  • 資料庫的表
    • 生物科技企業數(1999年至2006年)
    • 政府對生物科技研發工作的投資金額(1999年至2006年)
    • 民間對生物科技研發工作的投資金額(1999年至2006年)
    • HIV患者人數(1999年至2006年)
    • AIDS的死亡率(1999年至2006年)

目錄

Abstract

This Frost & Sullivan research service titled HIV Drug Developments - Emerging Technologies provides information on HIV drugs, vaccines, and the microbicides sector. The study focuses on novel, emerging technologies and novel applications of existing technologies in context with HIV drug development. It also covers advances in research and development (R&D), product development, and regulatory aspects specifically related to the emerging technologies in HIV drug development.

This analysis is available through our Technical Insights Growth Partnership Services program. With this program, clients receive industry-leading market research such as this, along with technical and econometric data as well as many interactive features including Analyst Inquiry Time and Client Councils.

Frost & Sullivan Growth Partnership Service

Based on extensive and in-depth research, real-world consulting work, and new theories tested in hundreds of companies across many industries, Frost & Sullivan has evolved its Growth Partnership Services (GPS) program that provides established and emerging firms with powerful growth visions. Moving beyond token mission statements, GPS provides an actionable vision to growth consulting partners by illustrating how key intelligence and strategic research based on defined goals can guide day-to-day behavior and overall company direction. The foundation of Frost & Sullivan's GPS includes:

  • Assisting companies to reach their full potential in the core business
  • Providing growth strategies to help companies expand into related businesses
  • Preemptively redefining the core business during market turbulence
  • Applying the Frost & Sullivan framework to identify and address common mistakes resulting from misaligned corporate strategies
  • Recommending growth management strategies through continuous partnership

To maximize the potential for growth within a firm's internal and external environment, Frost & Sullivan consultants can facilitate the creation of strategic programs that deliver improved market success. Frost & Sullivan's strengths lie in combining strategic understanding with market expertise and applying these with absolute commitment to its clients' growth.

Table of Contents

1. Executive Summary

  • 1. Introduction
    • 1. Introduction to HIV
    • 2. Prevalence
  • 2. Scope and Methodology
    • 1. Scope
    • 2. Methodology

2. Technology and Applications View Point

  • 1. Technology Primer
    • 1. Drugs
    • 2. Vaccines
    • 3. Microbicides
    • 4. The Red Ribbon Project
  • 2. Trends and Important Clinical Trials
    • 1. In Development
    • 2. Global Scenario
    • 3. Important Clinical Trials

3. Technology Adoption Factor Analysis

  • 1. Drivers and Challenges
    • 1. Drivers
    • 2. Challenges
  • 2. Regulatory Hurdles and Funding
    • 1. Regulatory Hurdles
    • 2. Funding

4. Technological Advancements--Drugs

  • 1. Technological Advancements--Companies
    • 1. Viral Entry Inhibitor-Based Monoclonal Antibody for HIV Treatment--USA
    • 2. Novel Entry Inhibitor-Based Drug for Protecting Healthy Cells from HIV Infection--Canada
    • 3. Innovative Entry Inhibitor-Based Drug Pipeline as HIV Therapeutics--USA
    • 4. Nucleoside Reverse Transcriptase Inhibitor Drug-Based Therapy for Prevention of HIV Infection--USA
    • 5. Drug Preventing the Action of Enzyme Required for Replication--USA
    • 6. Entry Inhibitor-Based Drug for Prevention of HIV Infection--USA
    • 7. Reverse Transcriptase Enzyme Inhibitor for Prevention of Fresh Infection of Cells--USA
    • 8. Telomerase-Based Drug for Enhancing Antiviral Activity Targeting HIV Infection--China
  • 2. Technological Advancements--Research Institutions
    • 1. Dynamic Host-Viral Interactions to Aid in Drug Development
    • 2. Scientists Reveal the Molecule Involved in HIV Integration with Host Genetic Component

5. Technological Advancements--Vaccines and Microbicides

  • 1. Technological Advancements in Companies--Vaccines
    • 1. AdVac-Based Vaccines to Tackle HIV--Netherlands
    • 2. DNA-Based Vaccine for HIV--U.S.
    • 3. Monoclonals for Blocking HIV--U.S.
    • 4. Plant-Based HIV vaccines--U.S.
    • 5. Therapore Technology-Based HIV Vaccine--U.S.
    • 6. Dendritic Cell Technology for AIDS Vaccine--United Kingdom
  • 2. Technological Advanvements in Companies--Mictrobicides
    • 1. Gel Based Microbicide for the Prevention of HIV Infection--Canada
    • 2. Microbicide Based Gel Tackling HIV Infection--Australia
    • 3. Microbicide-Based Gel for Counter-Attacking HIV Infection--U.S.
    • 4. Oligonucleotide-Based Microbicide for HIV Prevention--U.S.
  • 3. Research Institutions
    • 1. Vaccine to Tackle HIV Using Genetically Modified Tobacco--UK
    • 2. Retroviral-Based Approach for Interfering with HIV Replication--India
    • 3. Liposome-Based Adjuvant for Development of Vaccines--India
    • 4. Adenovector-Based Vaccine to Target HIV--U.S.
    • 5. Novel Targets for Antiviral Approach against HIV--India
    • 6. Plant-Based Vaccine for HIV--Russia

6. Key Patents; Contacts; and Glossary

  • 1. Key Patents
    • 1. Patents--Drugs and Developments
    • 2. Patents--Vaccines
  • 2. Contacts and Glossary
    • 1. Contacts
    • 2. Glossary

7. Frost & Sullivan 2006 Science & Technology Awards

  • 1. Technology Innovation Award
    • 1. Award Description
    • 2. Award Recipient
  • 2. Excellence in Technology Award
    • 1. Award Description.
    • 2. Award Recipient
  • 3. Excellence in Research Award
    • 1. Award Description
    • 2. Award Recipient

8. Decision Support Database

  • 1. Database Tables
    • 1. Number of Biotech Companies (1999-2006)
    • 2. Government Investment in Biotech R&D (1999-2006)
    • 3. Private Investment in Biotech (1999-2006)
    • 4. HIV Prevalence (1999-2006)
    • 5. AIDS Mortality (1999-2006)
Back to Top